Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2009, Article ID 937352, 10 pages
http://dx.doi.org/10.1155/2009/937352
Review Article

Aspirin Resistance

1Division of Cardiology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon
2Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon

Received 24 October 2008; Revised 9 February 2009; Accepted 15 February 2009

Academic Editor: Charles S. Greenberg

Copyright © 2009 Khaled Mansour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. The Second International Study of Infarct Survival Collaborative Group, “Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2,” The Lancet, vol. 2, no. 8607, pp. 349–360, 1988. View at Google Scholar
  2. Antithrombotic Trialists' Collaboration, “Collaborative overview of randomised trials of antiplatelet therapy—II: maintenance of vascular graft or arterial patency by antiplatelet therapy,” British Medical Journal, vol. 308, no. 6922, pp. 159–168, 1994. View at Google Scholar
  3. Antithrombotic Trialists' Collaboration, “Collaborative overview of randomised trials of antiplatelet therapy—III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients,” British Medical Journal, vol. 308, no. 6923, pp. 235–246, 1994. View at Google Scholar
  4. C. Baigent, C. Sudlow, R. Collins, and R. Peto, “Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients,” British Medical Journal, vol. 324, no. 7329, pp. 71–86, 2002. View at Publisher · View at Google Scholar
  5. P. Marson and G. Pasero, “The Italian contributions to the history of salicylates,” Reumatismo, vol. 58, no. 1, pp. 66–75, 2006. View at Google Scholar
  6. H. Lévesque and O. Lafont, “Aspirin throughout the ages: an historical review,” La Revue de Médecine Interne, vol. 21, pp. S8–S17, 2000. View at Publisher · View at Google Scholar
  7. J. R. Vane, “The fight against rheumatism: from willow bark to COX-1 sparing drugs,” Journal of Physiology and Pharmacology, vol. 51, no. 4, part 1, pp. 573–586, 2000. View at Google Scholar
  8. H. Vainio and G. Morgan, “Aspirin for the second hundred years: new uses for an old drug,” Pharmacology and Toxicology, vol. 81, no. 4, pp. 151–152, 1997. View at Publisher · View at Google Scholar
  9. C. Patrono, L. A. García Rodríguez, R. Landolfi, and C. Baigent, “Low-dose aspirin for the prevention of atherothrombosis,” The New England Journal of Medicine, vol. 353, no. 22, pp. 2373–2383, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. A. D. Michelson, M. Cattaneo, J. W. Eikelboom et al., “Aspirin resistance: position paper of the Working Group on Aspirin Resistance,” Journal of Thrombosis and Haemostasis, vol. 3, no. 6, pp. 1309–1311, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. G. J. Hankey and J. W. Eikelboom, “Aspirin resistance,” The Lancet, vol. 367, no. 9510, pp. 606–617, 2006. View at Publisher · View at Google Scholar · View at PubMed
  12. T. H. Wang, D. L. Bhatt, and E. J. Topol, “Aspirin and clopidogrel resistance: an emerging clinical entity,” European Heart Journal, vol. 27, no. 6, pp. 647–654, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. E. D. Michos, R. Ardehali, R. S. Blumenthal, R. A. Lange, and H. Ardehali, “Aspirin and clopidogrel resistance,” Mayo Clinic Proceedings, vol. 81, no. 4, pp. 518–526, 2006. View at Publisher · View at Google Scholar
  14. A. D. Michelson, “Platelet function testing in cardiovascular diseases,” Circulation, vol. 110, no. 19, pp. e489–e493, 2004. View at Publisher · View at Google Scholar · View at PubMed
  15. C. H. Hennekens, K. Schror, S. Weisman, and G. A. FitzGerald, “Terms and conditions: semantic complexity and aspirin resistance,” Circulation, vol. 110, no. 12, pp. 1706–1708, 2004. View at Publisher · View at Google Scholar · View at PubMed
  16. J. Mehta, P. Mehta, C. Burger, and C. J. Pepine, “Platelet aggregation studies in coronary artery disease: past 4. Effect of aspirin,” Atherosclerosis, vol. 31, no. 2, pp. 169–175, 1978. View at Publisher · View at Google Scholar
  17. P. A. Gurbel and U. S. Tantry, “Clopidogrel resistance?,” Thrombosis Research, vol. 120, no. 3, pp. 311–321, 2007. View at Publisher · View at Google Scholar · View at PubMed
  18. P. André, S. M. Delaney, T. LaRocca et al., “P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries,” The Journal of Clinical Investigation, vol. 112, no. 3, pp. 398–406, 2003. View at Publisher · View at Google Scholar
  19. S. Sanderson, J. Emery, T. Baglin, and A.-L. Kinmonth, “Narrative review: aspirin resistance and its clinical implications,” Annals of Internal Medicine, vol. 142, no. 5, pp. 370–380, 2005. View at Google Scholar
  20. L. Macchi, N. Sorel, and L. Christiaens, “Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance,” Current Pharmaceutical Design, vol. 12, no. 2, pp. 251–258, 2006. View at Publisher · View at Google Scholar
  21. E. Shantsila, T. Watson, and G. Y. H. Lip, “Aspirin resistance: what, why and when?,” Thrombosis Research, vol. 119, no. 5, pp. 551–554, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. T. S. Poulsen, B. Jørgensen, L. Korsholm, P. B. Licht, T. Haghfelt, and H. Mickley, “Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction,” Thrombosis Research, vol. 119, no. 5, pp. 555–562, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. A. J. Grau, S. Reiners, C. Lichy, F. Buggle, and A. Ruf, “Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study,” Stroke, vol. 34, no. 4, pp. 849–854, 2003. View at Publisher · View at Google Scholar · View at PubMed
  24. S. Ziegler, T. Maca, E. Alt, W. Speiser, B. Schneider, and E. Minar, “Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patients,” Platelets, vol. 13, no. 8, pp. 493–497, 2002. View at Publisher · View at Google Scholar · View at PubMed
  25. K. Grundmann, K. Jaschonek, B. Kleine, J. Dichgans, and H. Topka, “Aspirin non-responder status in patients with recurrent cerebral ischemic attacks,” Journal of Neurology, vol. 250, no. 1, pp. 63–66, 2003. View at Publisher · View at Google Scholar · View at PubMed
  26. L. Macchi, L. Christiaens, S. Brabant et al., “Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate,” Thrombosis Research, vol. 107, no. 1-2, pp. 45–49, 2002. View at Publisher · View at Google Scholar
  27. J. M. ten Berg, W. B. M. Gerritsen, F. J. L. M. Haas, H. C. Kelder, F. W. A. Verheugt, and H. W. Thijs Plokker, “High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention,” Thrombosis Research, vol. 105, no. 5, pp. 385–390, 2002. View at Publisher · View at Google Scholar
  28. P. A. Gum, K. Kottke-Marchant, E. D. Poggio et al., “Profile and prevalence of aspirin resistance in patients with cardiovascular disease,” American Journal of Cardiology, vol. 88, no. 3, pp. 230–235, 2001. View at Publisher · View at Google Scholar
  29. K. Andersen, M. Hurlen, H. Arnesen, and I. Seljeflot, “Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease,” Thrombosis Research, vol. 108, no. 1, pp. 37–42, 2002. View at Publisher · View at Google Scholar
  30. P. Harrison, H. Segal, K. Blasbery, C. Furtado, L. Silver, and P. M. Rothwell, “Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry,” Stroke, vol. 36, no. 5, pp. 1001–1005, 2005. View at Publisher · View at Google Scholar · View at PubMed
  31. D. L. Yee, B. R. Dinu, C. W. Sun et al., “Low prevalence and assay discordance of “aspirin resistance” in children,” Pediatric Blood & Cancer, vol. 51, no. 1, pp. 86–92, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. L. Christiaens, S. Ragot, J. Mergy, J. Allal, and L. Macchi, “Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study,” Blood Coagulation & Fibrinolysis, vol. 19, no. 3, pp. 235–239, 2008. View at Publisher · View at Google Scholar · View at PubMed
  33. B. Pamukcu, H. Oflaz, I. Onur et al., “Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR),” Blood Coagulation & Fibrinolysis, vol. 18, no. 2, pp. 187–192, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. B. Pamukcu, H. Oflaz, A. Oncul et al., “The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events,” Journal of Thrombosis and Thrombolysis, vol. 22, no. 2, pp. 103–110, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. O. M. Akay, Z. Canturk, E. Akin, C. Bal, and Z. Gulbas, “Aspirin-resistance frequency: a prospective study in 280 healthy Turkish volunteers,” Clinical and Applied Thrombosis/Hemostasis, vol. 15, no. 1, pp. 98–102, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. P.-Y. Lee, W.-H. Chen, W. Ng et al., “Low-dose aspirin increases aspirin resistance in patients with coronary artery disease,” The American Journal of Medicine, vol. 118, no. 7, pp. 723–727, 2005. View at Publisher · View at Google Scholar · View at PubMed
  37. G. H. R. Rao, “Influence of anti-platelet drugs on platelet-vessel wall interactions,” Prostaglandins, Leukotrienes and Medicine, vol. 30, no. 2-3, pp. 133–145, 1987. View at Publisher · View at Google Scholar
  38. J. Koutts, “Aspirin and coronary heart disease. Clinical applications,” Australian Family Physician, vol. 19, no. 2, pp. 217, 221–223, 1990. View at Google Scholar
  39. K. A. Louden, F. B. Pipkin, S. Heptinstall et al., “Neonatal platelet reactivity and serum thromboxane B2 production in whole blood: the effect of maternal low dose aspirin,” British Journal of Obstetrics and Gynaecology, vol. 101, no. 3, pp. 203–208, 1994. View at Google Scholar
  40. F. Bucchi, A. Bodzento, G. de Gaetano, and C. Cerletti, “Effects of 1 gram oral or intravenous aspirin on urinary excretion of thromboxane B2 and 6-keto-PGF1α in healthy subjects,” Prostaglandins, vol. 32, no. 5, pp. 691–701, 1986. View at Publisher · View at Google Scholar
  41. J. C. Frölich, “A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes,” Trends in Pharmacological Sciences, vol. 18, no. 1, pp. 30–34, 1997. View at Publisher · View at Google Scholar
  42. G. Cotter, E. Shemesh, M. Zehavi et al., “Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?,” American Heart Journal, vol. 147, no. 2, pp. 293–300, 2004. View at Publisher · View at Google Scholar · View at PubMed
  43. G. G. L. Biondi-Zoccai, M. Lotrionte, P. Agostoni et al., “A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease,” European Heart Journal, vol. 27, no. 22, pp. 2667–2674, 2006. View at Publisher · View at Google Scholar · View at PubMed
  44. D. Rottlaender, M. Scherner, T. Schneider, and E. Erdmann, “Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany,” Deutsche Medizinische Wochenschrift, vol. 132, no. 4, pp. 139–144, 2007. View at Publisher · View at Google Scholar · View at PubMed
  45. F. Catella-Lawson, M. P. Reilly, S. C. Kapoor et al., “Cyclooxygenase inhibitors and the antiplatelet effects of aspirin,” The New England Journal of Medicine, vol. 345, no. 25, pp. 1809–1817, 2001. View at Publisher · View at Google Scholar · View at PubMed
  46. B. S. Anand, S. K. Sanduja, and L. M. Lichtenberger, “Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers,” Gastroenterology, vol. 116, p. A371, 1999. View at Google Scholar
  47. P. Iñarrea, F. Esteva, R. Cornudella, and A. Lanas, “Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man,” Scandinavian Journal of Gastroenterology, vol. 35, no. 3, pp. 242–246, 2000. View at Publisher · View at Google Scholar
  48. M. K. Halushka and P. V. Halushka, “Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?,” Circulation, vol. 105, no. 14, pp. 1620–1622, 2002. View at Publisher · View at Google Scholar
  49. J. W. Eikelboom, J. Hirsh, J. I. Weitz, M. Johnston, Q. Yi, and S. Yusuf, “Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events,” Circulation, vol. 105, no. 14, pp. 1650–1655, 2002. View at Publisher · View at Google Scholar
  50. T. Goodman, A. Ferro, and P. Sharma, “Pharmacogenetics of aspirin resistance: a comprehensive systematic review,” British Journal of Clinical Pharmacology, vol. 66, no. 2, pp. 222–232, 2008. View at Publisher · View at Google Scholar · View at PubMed
  51. A. Szczeklik, A. Undas, M. Sanak, M. Frolow, and W. Węgrzyn, “Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa,” British Journal of Haematology, vol. 110, no. 4, pp. 965–967, 2000. View at Publisher · View at Google Scholar
  52. E. Papp, V. Havasi, J. Bene et al., “Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?,” Annals of Pharmacotherapy, vol. 39, no. 6, pp. 1013–1018, 2005. View at Publisher · View at Google Scholar · View at PubMed
  53. J. Dropinski, J. Musial, M. Sanak, W. Węgrzyn, R. Nizankowski, and A. Szczeklik, “Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease,” Thrombosis Research, vol. 119, no. 3, pp. 301–303, 2007. View at Publisher · View at Google Scholar · View at PubMed
  54. H. W. Cohen, J. P. Crandall, S. M. Hailpern, and H. H. Billett, “Aspirin resistance associated with HbA1c and obesity in diabetic patients,” Journal of Diabetes and Its Complications, vol. 22, no. 3, pp. 224–228, 2008. View at Publisher · View at Google Scholar · View at PubMed
  55. H. Ogawa, M. Nakayama, T. Morimoto et al., “Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial,” Journal of the American Medical Association, vol. 300, no. 18, pp. 2134–2141, 2008. View at Publisher · View at Google Scholar · View at PubMed
  56. J. Belch, A. MacCuish, I. Campbell et al., “The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease,” British Medical Journal, vol. 337, p. a1840, 2008. View at Publisher · View at Google Scholar
  57. N. Zimmermann, A. Wenk, U. Kim et al., “Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery,” Circulation, vol. 108, no. 5, pp. 542–547, 2003. View at Publisher · View at Google Scholar · View at PubMed
  58. N. Zimmermann, M. Kurt, A. Wenk, J. Winter, E. Gams, and T. Hohlfeld, “Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?,” European Journal of Cardio-Thoracic Surgery, vol. 27, no. 4, pp. 606–610, 2005. View at Publisher · View at Google Scholar · View at PubMed
  59. S. Guthikonda, E. I. Lev, R. Patel et al., “Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin,” Journal of Thrombosis and Haemostasis, vol. 5, no. 3, pp. 490–496, 2007. View at Publisher · View at Google Scholar · View at PubMed
  60. A. Modica, F. Karlsson, and T. Mooe, “Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection,” Journal of Thrombosis and Haemostasis, vol. 5, no. 3, pp. 507–511, 2007. View at Publisher · View at Google Scholar · View at PubMed
  61. P. Harrison, “Platelet function analysis,” Blood Reviews, vol. 19, no. 2, pp. 111–123, 2005. View at Publisher · View at Google Scholar · View at PubMed
  62. N. S. Nicholson, S. G. Panzer-Knodle, N. F. Haas et al., “Assessment of platelet function assays,” American Heart Journal, vol. 135, no. 5, part 2, pp. S170–S178, 1998. View at Publisher · View at Google Scholar
  63. P. A. Gum, K. Kottke-Marchant, E. D. Poggio et al., “Profile and prevalence of aspirin resistance in patients with cardiovascular disease,” American Journal of Cardiology, vol. 88, no. 3, pp. 230–235, 2001. View at Publisher · View at Google Scholar
  64. E. F. Mammen, P. C. Comp, R. Gosselin et al., “PFA-100TM system: a new method for assessment of platelet dysfunction,” Seminars in Thrombosis and Hemostasis, vol. 24, no. 2, pp. 195–202, 1998. View at Publisher · View at Google Scholar
  65. L. Christiaens, S. Ragot, J. Mergy, J. Allal, and L. Macchi, “Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study,” Blood Coagulation & Fibrinolysis, vol. 19, no. 3, pp. 235–239, 2008. View at Publisher · View at Google Scholar · View at PubMed
  66. J. L. Coleman, J. C. Wang, and D. I. Simon, “Determination of individual response to aspirin therapy using the Accumetrics Ultegra RFPA-ASA system,” Point of Care, vol. 3, no. 2, pp. 77–82, 2004. View at Google Scholar
  67. H. L. Nielsen, S. D. Kristensen, S. S. Thygesen et al., “Aspirin response evaluated by the VerifyNowTM Aspirin System and Light Transmission Aggregometry,” Thrombosis Research, vol. 123, no. 2, pp. 267–273, 2008. View at Publisher · View at Google Scholar · View at PubMed
  68. R. G. Hart, A. D. Leonard, R. L. Talbert et al., “Aspirin dosage and thromboxane synthesis in patients with vascular disease,” Pharmacotherapy, vol. 23, no. 5, pp. 579–584, 2003. View at Publisher · View at Google Scholar
  69. A. Bruno, J. P. McConnell, S. N. Cohen et al., “Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction,” Stroke, vol. 35, no. 3, pp. 727–730, 2004. View at Publisher · View at Google Scholar · View at PubMed
  70. M. Lordkipanidzé, C. Pharand, E. Schampaert, J. Turgeon, D. A. Palisaitis, and J. G. Diodati, “A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease,” European Heart Journal, vol. 28, no. 14, pp. 1702–1708, 2007. View at Publisher · View at Google Scholar · View at PubMed
  71. G. Krasopoulos, S. J. Brister, W. S. Beattie, and M. R. Buchanan, “Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis,” British Medical Journal, vol. 336, no. 7637, pp. 195–198, 2008. View at Publisher · View at Google Scholar · View at PubMed
  72. J. D. Snoep, M. M. C. Hovens, J. C. J. Eikenboom, J. G. van der Bom, and M. V. Huisman, “Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis,” Archives of Internal Medicine, vol. 167, no. 15, pp. 1593–1599, 2007. View at Publisher · View at Google Scholar · View at PubMed
  73. N. A. Englyst, G. Horsfield, J. Kwan, and C. D. Byrne, “Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity,” Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 6, pp. 1196–1203, 2008. View at Publisher · View at Google Scholar · View at PubMed
  74. W.-H. Chen, X. Cheng, P.-Y. Lee et al., “Aspirin resistance and adverse clinical events in patients with coronary artery disease,” The American Journal of Medicine, vol. 120, no. 7, pp. 631–635, 2007. View at Publisher · View at Google Scholar · View at PubMed
  75. W.-H. Chen, P.-Y. Lee, W. Ng, H.-F. Tse, and C.-P. Lau, “Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment,” Journal of the American College of Cardiology, vol. 43, no. 6, pp. 1122–1126, 2004. View at Publisher · View at Google Scholar · View at PubMed
  76. M. Frossard, I. Fuchs, J. M. Leitner et al., “Platelet function predicts myocardial damage in patients with acute myocardial infarction,” Circulation, vol. 110, no. 11, pp. 1392–1397, 2004. View at Publisher · View at Google Scholar · View at PubMed
  77. G. Campo, M. Valgimigli, D. Gemmati et al., “Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention. Insights into the STRATEGY study,” Journal of the American College of Cardiology, vol. 48, no. 11, pp. 2178–2185, 2006. View at Publisher · View at Google Scholar · View at PubMed
  78. G. Barone-Rochette, O. Ormezzano, B. Polack, G. Vanzetto, B. Bertrand, and J. Machecourt, “Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases,” Archives of Cardiovascular Diseases, vol. 101, no. 2, pp. 100–107, 2008. View at Publisher · View at Google Scholar
  79. N. Faraday, L. R. Yanek, R. Mathias et al., “Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1,” Circulation, vol. 115, no. 19, pp. 2490–2496, 2007. View at Publisher · View at Google Scholar · View at PubMed
  80. A. Assadian, J. Lax, U. Meixner-Loicht, G. W. Hagmüller, P. M. Bayer, and W. Hübl, “Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition,” Journal of Vascular Surgery, vol. 45, no. 6, pp. 1142–1147, 2007. View at Publisher · View at Google Scholar · View at PubMed
  81. D. J. Fitzgerald and A. Maree, “Aspirin and clopidogrel resistance,” Hematology, vol. 2007, no. 1, pp. 114–120, 2007. View at Google Scholar
  82. P.-Y. Lee, W.-H. Chen, W. Ng et al., “Low-dose aspirin increases aspirin resistance in patients with coronary artery disease,” The American Journal of Medicine, vol. 118, no. 7, pp. 723–727, 2005. View at Publisher · View at Google Scholar · View at PubMed
  83. S. Derry and Y. K. Loke, “Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis,” British Medical Journal, vol. 321, no. 7270, pp. 1183–1187, 2000. View at Publisher · View at Google Scholar
  84. C. L. Campbell, S. Smyth, G. Montalescot, and S. R. Steinhubl, “Aspirin dose for the prevention of cardiovascular disease: a systematic review,” Journal of the American Medical Association, vol. 297, no. 18, pp. 2018–2024, 2007. View at Publisher · View at Google Scholar · View at PubMed
  85. C. Borna, E. Lazarowski, C. van Heusden, H. Öhlin, and D. Erlinge, “Resistance to aspirin in increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels,” Thrombosis Journal, vol. 3, article 10, pp. 1–9, 2005. View at Publisher · View at Google Scholar · View at PubMed
  86. J. W. Eikelboom, G. J. Hankey, J. Thom et al., “Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial,” Journal of Thrombosis and Haemostasis, vol. 3, no. 12, pp. 2649–2655, 2005. View at Publisher · View at Google Scholar · View at PubMed
  87. T. H. Wang, D. L. Bhatt, K. A. A. Fox et al., “An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial,” European Heart Journal, vol. 28, no. 18, pp. 2200–2207, 2007. View at Publisher · View at Google Scholar · View at PubMed
  88. D. L. Bhatt, M. D. Flather, W. Hacke et al., “Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial,” Journal of the American College of Cardiology, vol. 49, no. 19, pp. 1982–1988, 2007. View at Publisher · View at Google Scholar · View at PubMed
  89. The ESPS-2 Group, “European stroke prevention study 2: efficacy and safety data,” Journal of the Neurological Sciences, vol. 151, pp. S1–S77, 1997. View at Google Scholar
  90. P. H. Halkes, J. van Gijn, L. J. Kappelle, P. J. Koudstaal, and A. Algra, “Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial,” The Lancet, vol. 367, no. 9523, pp. 1665–1673, 2006. View at Publisher · View at Google Scholar · View at PubMed
  91. E. De Schryver, A. Algra, and J. van Gijn, “Dipyridamole for preventing stroke and other vascular events in patients with vascular disease,” Cochrane Database of Systematic Reviews, vol. 18, no. 3, Article ID CD001820, 2007. View at Publisher · View at Google Scholar · View at PubMed
  92. G. B. Boncoraglio, A. Bodini, C. Brambilla, E. Corsini, M. R. Carriero, and E. A. Parati, “Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease,” Clinical Neurology and Neurosurgery, vol. 111, no. 3, pp. 270–273, 2009. View at Publisher · View at Google Scholar · View at PubMed
  93. M. Gent, “A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE),” The Lancet, vol. 348, no. 9038, pp. 1329–1339, 1996. View at Publisher · View at Google Scholar
  94. R. L. Sacco, R. Adams, G. Albers et al., “Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association council on stroke: co-sponsored by the council on cardiovascular radiology and intervention. The American Academy of Neurology affirms the value of this guideline,” Stroke, vol. 37, no. 2, pp. 577–617, 2006. View at Publisher · View at Google Scholar · View at PubMed
  95. H.-C. Diener, J. Bogousslavsky, L. M. Brass et al., “Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 364, no. 9431, pp. 331–337, 2004. View at Publisher · View at Google Scholar · View at PubMed
  96. S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni, and K. K. Fox, “Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” The New England Journal of Medicine, vol. 345, no. 7, pp. 494–502, 2001. View at Publisher · View at Google Scholar